Steatotic liver disease among lean and non-lean individuals in Southern Lao PDR: a cross-sectional study of risk factors

被引:3
|
作者
Homsana, Anousin [1 ,2 ,3 ]
Southisavath, Phonesavanh [1 ,2 ,3 ,4 ]
Kling, Kerstin [5 ]
Hattendorf, Jan [2 ,3 ]
Vorasane, Savina [4 ]
Paris, Daniel Henry [2 ,3 ]
Sayasone, Somphou [1 ]
Odermatt, Peter [2 ,3 ]
Probst-Hensch, Nicole [2 ,3 ]
机构
[1] Minist Hlth, Lao Trop & Publ Hlth Inst, Vientiane Capital, Laos
[2] Swiss Trop & Publ Hlth Inst, CH-4123 Allschwil, Switzerland
[3] Univ Basel, Basel, Switzerland
[4] Minist Hlth, Dept Radiol, Mahosot Hosp, Vientiane Capital, Laos
[5] Robert Koch Inst, Immunizat Unit, Berlin, Germany
基金
瑞士国家科学基金会;
关键词
Lao PDR; steatotic liver disease; hepatic steatosis; metabolic dysfunction-associated steatotic liver disease; type 2 diabetes mellitus; metabolic diseases; opisthorchis viverrini; lipids; FATTY; DIAGNOSIS;
D O I
10.1080/07853890.2024.2329133
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Steatotic liver disease (SLD) prevalence is rising worldwide, linked to insulin resistance and obesity. SLD prevalence can surpass 10% even among those with normal weight. In Lao People's Democratic Republic (Lao PDR), where Opisthorchis viverrini (OV) trematode infection and type 2 diabetes mellitus (T2DM) are common, infection related liver morbidity such as cholangiocarcinoma (CCA) is high, but data on SLD prevalence is lacking. The objective of this study was to estimate the prevalence and explore determinants of SLD in rural southern Lao PDR for lean and non-lean populations. Method: A cross-sectional community-based study assessed SLD prevalence using abdominal ultrasonography (US). Factors investigated for association with SLD were identified by interview, serological tests (Hepatitis B surface antigen (HBsAg); lipids and HbA1c), anthropometrical measurements, and parasitological assessments (OV infection). Uni- and multivariable logistic regression analyses with SLD as endpoint were conducted separately for lean (body mass index (BMI) <23.0 kg/m(2)) and non-lean (BMI >= 23.0 kg/m(2)) participants. Result: 2,826 participants were included. SLD prevalence was 27.1% (95% confidence interval (95% CI) 24.0%-30.4%), higher among non-lean (39.8%) than lean individuals (17.4%). Lean individuals with OV infection had a statistically significant association with lower odds of SLD (adjusted odds ratio (aOR) 0.49, 95% CI 0.33 - 0.73). T2DM showed a significant positive association with SLD in both lean (aOR 3.58, 95% CI 2.28 - 5.63) and non-lean individuals (aOR 3.31, 95% CI 2.31 - 4.74) while dyslipidemia was significantly associated only in the non-lean group (aOR 1.83, 95% CI 1.09 - 3.07). Females participants exhibited elevated odds of SLD in both lean (aOR 1.43, 95% CI 1.02 - 2.01) and non-lean SLD (aOR 1.50, 95% CI 1.12 - 2.01). Conclusion: SLD prevalence is notably high among Laotian adults in rural areas, particularly in females and in non-lean individuals. Lean individuals with OV infection exhibited lower SLD prevalence. SLD was more prevalent in individuals with T2DM, independent of BMI. SLD adds to the burden of infection-related liver morbidity in Lao PDR.
引用
收藏
页数:16
相关论文
共 50 条
  • [31] Provider performance in treating poor patients - factors influencing prescribing practices in lao PDR: a cross-sectional study
    Syhakhang, Lamphone
    Soukaloun, Douangdao
    Tomson, Goran
    Petzold, Max
    Rehnberg, Clas
    Wahlstrom, Rolf
    BMC HEALTH SERVICES RESEARCH, 2011, 11
  • [32] Provider performance in treating poor patients - factors influencing prescribing practices in lao PDR: a cross-sectional study
    Lamphone Syhakhang
    Douangdao Soukaloun
    Göran Tomson
    Max Petzold
    Clas Rehnberg
    Rolf Wahlström
    BMC Health Services Research, 11
  • [33] Menstrual hygiene management and menstrual secrecy among young women in rural Lao PDR: A cross-sectional study
    Ono, Kanayo
    Sato, Yu
    Kuwano, Noriko
    Ando, Hisao
    PLOS ONE, 2024, 19 (11):
  • [34] Nonalcoholic Fatty Liver Disease in Lean Subjects: Associations With Metabolic Dysregulation and Cardiovascular Risk-A Single-Center Cross-Sectional Study
    Semmler, Georg
    Wernly, Sarah
    Bachmayer, Sebastian
    Wernly, Bernhard
    Schwenoha, Lena
    Huber-Schonauer, Ursula
    Stickel, Felix
    Niederseer, David
    Aigner, Elmar
    Datz, Christian
    CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2021, 12 (04) : E00326
  • [35] Increased risk of reflux esophagitis in non-obese individuals with nonalcoholic fatty liver disease: a cross-sectional study
    Qiu, Peihong
    Du, Juan
    Zhang, Cheng
    Li, Mengting
    Li, Hongliang
    Chen, Changxi
    ANNALS OF MEDICINE, 2023, 55 (02)
  • [36] Impact of nonalcoholic fatty liver disease on the risk of gallbladder polyps in lean and non-obese individuals: A cohort study
    Nam Hee Kim
    Ji Hun Kang
    Hong Joo Kim
    Hepatobiliary & Pancreatic Diseases International, 2024, 23 (06) : 573 - 578
  • [37] Impact of nonalcoholic fatty liver disease on the risk of gallbladder polyps in lean and non-obese individuals: A cohort study
    Kim, Nam Hee
    Kang, Ji Hun
    Kim, Hong Joo
    HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2024, 23 (06) : 573 - 578
  • [38] Cardiovascular disease risk factors among school children of Bangladesh: a cross-sectional study
    Islam, T. M. Manjurul
    Banik, Palash Chandra
    Barua, Lingkan
    Shariful Islam, Sheikh Mohammed
    Chowdhury, Shahanaz
    Ahmed, M. S. A. Mansur
    BMJ OPEN, 2020, 10 (10):
  • [39] Chronic disease risk factors among hospital employees: A cross-sectional study in Turkiye
    Medeni, Volkan
    Topcu, Vildan
    Bozdag, Fatma
    Medeni, Irem
    PLOS ONE, 2025, 20 (01):
  • [40] Prevalence and risk factors of metabolic dysfunction-associated steatotic liver disease in south Central Uganda: A cross-sectional survey
    Enriquez, Rocio
    Homsi, Mahmoud
    Ssekubugu, Robert
    Nabukalu, Dorean
    Zeebari, Zangin
    Marrone, Gaetano
    Gigante, Bruna
    Chang, Larry W.
    Reynolds, Steven J.
    Nalugoda, Fred
    Ekstroem, Anna Mia
    Hagstroem, Hannes
    Nordenstedt, Helena
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 59 (09) : 1111 - 1121